Chemomab Therapeutics Ltd DRC (CMMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.31M
Last updated: Nov 17, 2026 at 11:01 AM ET
Chemomab Therapeutics Ltd DRC (CMMB) Stock Forecast
Analysts expect Chemomab Therapeutics Ltd DRC (CMMB) to earn -$0.02 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.03.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.02
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.03
- EPS consensus
- Fiscal year ending Dec 31, 2028
- -$0.04
- EPS consensus
- Next report
- Mar 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.02 | -$0.02 to -$0.02 | 1 |
| Dec 31, 2027 | -$0.03 | -$0.03 to -$0.03 | 1 |
| Dec 31, 2028 | -$0.04 | -$0.04 to -$0.04 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.27 to $0.00 | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.03 | -$0.03 | -$0.03 | -$0.04 | -$0.04 | N/A |
Frequently Asked Questions About CMMB
What is the CMMB stock forecast?
Consensus analyst estimates put Chemomab Therapeutics Ltd DRC's EPS at -$0.02 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from CMMB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.02, with estimates from -$0.02 to -$0.02 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.03, with estimates from -$0.03 to -$0.03 from 1 analyst.
How many analysts cover CMMB?
1 analyst estimates EPS for Chemomab Therapeutics Ltd DRC for the fiscal year ending Dec 31, 2026.
CMMB pages: Overview, Earnings, Forecast, Competitors